Arvinas Inc
ARVN13.480USD
+0.520+4.01%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
954.38MMarket Cap
LossP/E TTM
More Details of Arvinas Inc Company
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Arvinas Inc Info
Ticker SymbolARVN
Company nameArvinas Inc
IPO dateSep 27, 2018
CEODr. John G. Houston, Ph.D.
Number of employees430
Security typeOrdinary Share
Fiscal year-endSep 27
Address5 Science Park
CityNEW HAVEN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code06511-1966
Phone12035351456
Websitehttps://www.arvinas.com/
Ticker SymbolARVN
IPO dateSep 27, 2018
CEODr. John G. Houston, Ph.D.
Company Executives of Arvinas Inc
Name
Name/Position
Position
Shareholding
Change
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Ms. Linda C. Bain
Ms. Linda C. Bain
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Feb 5
Updated: Thu, Feb 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.23%
BlackRock Institutional Trust Company, N.A.
8.05%
Pfizer Inc
5.38%
D. E. Shaw & Co., L.P.
5.30%
Logos Global Management LP
3.89%
Other
66.13%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.23%
BlackRock Institutional Trust Company, N.A.
8.05%
Pfizer Inc
5.38%
D. E. Shaw & Co., L.P.
5.30%
Logos Global Management LP
3.89%
Other
66.13%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.71%
Hedge Fund
26.23%
Investment Advisor/Hedge Fund
21.31%
Venture Capital
6.56%
Corporation
5.38%
Research Firm
4.23%
Individual Investor
2.59%
Pension Fund
0.53%
Bank and Trust
0.31%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
513
61.93M
168.36%
-2.99M
2025Q3
525
64.92M
150.53%
-4.18M
2025Q2
518
67.55M
122.76%
+4.71M
2025Q1
504
63.19M
117.99%
-22.92M
2024Q4
484
75.18M
115.79%
+228.04K
2024Q3
476
75.20M
114.63%
+1.35M
2024Q2
469
73.21M
109.58%
+2.16M
2024Q1
476
70.86M
103.71%
+13.21K
2023Q4
483
66.87M
80.36%
+15.93M
2023Q3
458
50.77M
99.64%
+2.00M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
8.55M
13.31%
-831.93K
-8.87%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.17M
8.05%
-87.00K
-1.65%
Sep 30, 2025
Pfizer Inc
3.46M
5.38%
--
--
Sep 30, 2025
D. E. Shaw & Co., L.P.
3.41M
5.3%
+57.86K
+1.73%
Nov 06, 2025
Logos Global Management LP
2.50M
3.89%
-3.08M
-55.16%
Oct 14, 2025
Millennium Management LLC
2.13M
3.32%
+233.48K
+12.30%
Sep 30, 2025
State Street Investment Management (US)
1.87M
2.92%
+140.76K
+8.13%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.67M
2.6%
+85.09K
+5.37%
Sep 30, 2025
TCG Crossover Management, LLC
1.62M
2.52%
+1.62M
--
Sep 30, 2025
New Leaf Venture Partners LLC
1.59M
2.47%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.76%
State Street SPDR S&P Pharmaceuticals ETF
1.65%
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Invesco NASDAQ Future Gen 200 ETF
0.7%
iShares U.S. Pharmaceuticals ETF
0.28%
Federated Hermes MDT Small Cap Core ETF
0.24%
Zacks Small/Mid Cap ETF
0.22%
iShares Health Innovation Active ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco RAFI US 1500 Small-Mid ETF
0.1%
View more
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.76%
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.65%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.91%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.7%
iShares U.S. Pharmaceuticals ETF
Proportion0.28%
Federated Hermes MDT Small Cap Core ETF
Proportion0.24%
Zacks Small/Mid Cap ETF
Proportion0.22%
iShares Health Innovation Active ETF
Proportion0.16%
ProShares Ultra Nasdaq Biotechnology
Proportion0.11%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
